Clinical and Contrast-Enhanced Ultrasound Echography Outcomes in Psoriatic Arthritis Patients after One Year of Continuous Therapy with Anti-TNF Drugs

Table 2

Demographic, clinical, and CEUS characteristics of the patients before and at 12 months of anti-TN therapy.

Patient number	Gender	Age	Duration; Pso (yrs)	Duration; PsA (yrs)	Therapy	Month 0						Month 12
						TJC	SJC	Dactylitis	Enthesitis	CEUS	PASI	TJC	SJC	Dactylitis	Enthesitis	CEUS	PASI
1	F	37	22	2	Adalimumab	10	0	No	No	2	0.2	10	0	No	No	1	1.0
2	M	45	24	15	Etanercept	18	1	No	No	3	3.7	0	0	No	No	0	0.0
3	F	27	25	3	Etanercept	19	0	No	Yes	3	0.0	0	0	No	No	0	0.0
4	F	48	6	<1	Adalimumab	48	7	Yes	No	2	0.9	51	0	No	Yes	2	0.0
5	M	55	3	3	Adalimumab	4	2	Yes	No	3	2.8	1	0	No	No	1	0.0
6	F	47	27	1	Adalimumab	12	3	No	Yes	3	10	4	0	No	Yes	1	2.4
7	F	63	21	21	Adalimumab	11	2	No	Yes	3	2.0	0	0	No	No	1	1.6
8	F	64	24	3	Etanercept	3	0	No	Yes	3	3.1	0	0	No	No	2	0.0
9	F	54	40	7	Etanercept	3	2	No	No	2	2.9	4	1	No	No	0	1.9
10	F	66	32	<1	Etanercept	10	6	No	No	1	2.7	8	0	No	No	0	0.8
11	M	48	4	1.5	Etanercept	17	2	Yes	Yes	3	1.2	1	1	No	No	0	0.0
12	M	58	24	14	Etanercept	1	1	No	No	0	2.7	0	0	No	No	0	0.0
13	M	41	23	1	Etanercept	2	1	No	No	2	2.6	0	0	No	No	0	0.0
14	M	54	36	16	Adalimumab	8	0	No	No	1	9.6	10	0	No	No	1	6.6
15	M	43	28	22	Adalimumab	17	6	No	Yes	3	20.4	1	0	No	Yes	0	0.0
16	F	59	46	20	Etanercept	2	2	Yes	No	0	3.2	0	0	No	No	0	1.8
17	M	36	2	1.5	Adalimumab	11	4	No	No	2	1.2	0	0	No	No	0	0.0
18	M	44	31	31	Etanercept	4	4	No	No	2	2.8	0	0	No	No	1	2.0
19	F	54	4	2	Adalimumab	15	3	No	Yes	3	2.4	15	0	No	Yes	1	0.0
20	F	51	15	<1	Adalimumab	8	2	No	Yes	3	0.8	2	0	No	No	1	0.0
21	M	62	10	<1	Etanercept	3	0	No	No	2	2.6	1	1	No	No	0	2.1
22	M	65	5	3	Etanercept	3	2	Yes	No	2	5.2	1	1	No	No	1	2.1
23	M	69	19	<1	Etanercept	6	0	No	No	0	5.9	0	0	No	No	0	5.0
24	F	29	8	3	Etanercept	10	1	No	No	1	0.2	0	0	No	Yes	1	0.0
25	M	45	24	2	Etanercept	9	2	Yes	No	3	4.5	0	0	No	No	0	3.6

TJC: tender joint count; SJC: swollen joint count; CEUS: contrast-enhanced ultrasound; PASI: Psoriasis Area Severity Index.